Prestige BioPharma Statistics

Total Valuation

KRX:950210 has a market cap or net worth of KRW 164.30 billion. The enterprise value is 246.96 billion.

Market Cap	164.30B
Enterprise Value	246.96B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

KRX:950210 has 12.02 million shares outstanding. The number of shares has decreased by -0.20% in one year.

Current Share Class	n/a
Shares Outstanding	12.02M
Shares Change (YoY)	-0.20%
Shares Change (QoQ)	-0.03%
Owned by Insiders (%)	30.40%
Owned by Institutions (%)	0.11%
Float	3.59M

Valuation Ratios

The trailing PE ratio is 52.10.

PE Ratio	52.10
Forward PE	n/a
PS Ratio	11.40
PB Ratio	0.33
P/TBV Ratio	0.45
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	15.67
EV / Sales	17.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.28

Financial Position

The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.25.

Current Ratio	1.17
Quick Ratio	0.92
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-1.69
Interest Coverage	-9.88

Financial Efficiency

Return on equity (ROE) is -1.07% and return on invested capital (ROIC) is -7.69%.

Return on Equity (ROE)	-1.07%
Return on Assets (ROA)	-6.58%
Return on Invested Capital (ROIC)	-7.69%
Return on Capital Employed (ROCE)	-13.27%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.02
Inventory Turnover	0.94

Taxes

Income Tax	-465.34M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.72% in the last 52 weeks. The beta is 0.98, so KRX:950210's price volatility has been similar to the market average.

Beta (5Y)	0.98
52-Week Price Change	-8.72%
50-Day Moving Average	12,791.20
200-Day Moving Average	13,868.60
Relative Strength Index (RSI)	64.24
Average Volume (20 Days)	131,928

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:950210 had revenue of KRW 14.41 billion and earned 15.76 billion in profits. Earnings per share was 262.37.

Revenue	14.41B
Gross Profit	-9.13B
Operating Income	-75.35B
Pretax Income	-5.73B
Net Income	15.76B
EBITDA	-52.16B
EBIT	-75.35B
Earnings Per Share (EPS)	262.37

Full Income Statement

Balance Sheet

The company has 134.81 billion in cash and 127.02 billion in debt, giving a net cash position of 7.79 billion or 648.46 per share.

Cash & Cash Equivalents	134.81B
Total Debt	127.02B
Net Cash	7.79B
Net Cash Per Share	648.46
Equity (Book Value)	499.31B
Book Value Per Share	6,794.93
Working Capital	24.92B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -44.54 billion and capital expenditures -30.67 billion, giving a free cash flow of -75.21 billion.

Operating Cash Flow	-44.54B
Capital Expenditures	-30.67B
Free Cash Flow	-75.21B
FCF Per Share	-6,257.34

Full Cash Flow Statement

Margins

Gross margin is -63.32%, with operating and profit margins of -522.83% and 109.33%.

Gross Margin	-63.32%
Operating Margin	-522.83%
Pretax Margin	-39.77%
Profit Margin	109.33%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

KRX:950210 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.20%
Shareholder Yield	0.20%
Earnings Yield	9.59%
FCF Yield	-45.77%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KRX:950210 has an Altman Z-Score of -0.36 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.36
Piotroski F-Score	4